» Articles » PMID: 10893589

Efficacy, Safety and Patient Satisfaction Outcomes of the AMS 700CX Inflatable Penile Prosthesis: Results of a Long-term Multicenter Study. AMS 700CX Study Group

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2000 Jul 14
PMID 10893589
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We performed a long-term multicenter study of the AMS 700CX 3-piece inflatable penile prosthesis, focusing on longevity, morbidity and patient satisfaction in men implanted up to 134 months with a median followup of 47.7 months.

Materials And Methods: We performed a large scale retrospective multicenter study in 2 phases. Phase 1 was a medical record review of 372 men who underwent implantation with the AMS 700CX penile prosthesis from 1987 to 1996 by 7 frequent penile prosthesis implanters. Phase 2 included a structured telephone interview of 207 patients by a neutral observer.

Results: For the 372 men in phase 1 mean device mechanical reliability plus or minus standard deviation was 92.1% + or - 3.3% after 3 and 86.2% + or - 4.6% after 5 years. Patient age was 21 to 79 years (mean 57.6 + or - 11.0) at implantation. The etiology of erectile dysfunction was vascular in 27.7% of the cases, Peyronie's disease in 16.9%, diabetes mellitus in 12.9% and radical surgery in 11.6%. Of the men 55.6% received previous treatment for erectile dysfunction. Postoperative infection and device malfunction developed in 3.2% and 17.5% of the cases, respectively. Of the 207 men interviewed in phase 2, 86% still had an AMS 700CX penile prosthesis implanted, including 87.1% with erection suitable for coitus. Currently 79% of those with a device use it at least twice monthly and 88.2% would recommend an implant to a relative or friend.

Conclusions: The AMS 700CX penile implant produced suitable erection and excellent patient satisfaction at long-term followup in the majority of men. Implant reliability is excellent and postoperative morbidity is low.

Citing Articles

Interim Results of Rigicon Penile Prosthesis Implantation in a Single Center: The Largest Series in Türkiye.

Karaman M, Guzel R, Kirkik D, Koca O Urol Res Pract. 2025; 50(4):234-239.

PMID: 39873434 PMC: 11883673. DOI: 10.5152/tud.2025.24122.


Inflatable penile prosthesis implantation in the outpatient setting is safe and feasible: a prospective, singe center study.

Fidel M, Shah J, Bal D, Roque C, Ko Y, Dhillon H Int J Impot Res. 2024; .

PMID: 39587255 DOI: 10.1038/s41443-024-01004-3.


Management of Post-RALP SUI and ED - What are and What Should we be Doing?.

Pereira T, Rust J, Bernie H Curr Urol Rep. 2024; 26(1):19.

PMID: 39546126 DOI: 10.1007/s11934-024-01249-x.


Risk factors for reoperation of inflatable penile prosthesis among an ethnically diverse urban population in a high-volume center.

Hawks-Ladds N, Babar M, Labagnara K, Loloi J, Patel R, Harandi A Int J Impot Res. 2024; 37(1):37-44.

PMID: 39187572 PMC: 11706775. DOI: 10.1038/s41443-024-00966-8.


Short-term revision rate of Rigicon Testi10 testicular prosthesis in adolescents and adults: a retrospective chart review.

Atwater B, Kirkik D, Wilson S, Koca O, Purohit R, Munoz Vera C Int J Impot Res. 2024; .

PMID: 38714783 DOI: 10.1038/s41443-024-00893-8.